The stock has a 36-month beta value of 0.59. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for NKTR is 179.37M, and at present, short sellers hold a 4.54% of that float. On May 08, 2025, the average trading volume of NKTR was 2.48M shares.
NKTR) stock’s latest price update
Nektar Therapeutics (NASDAQ: NKTR)’s stock price has soared by 1.47 in relation to previous closing price of 0.61. Nevertheless, the company has seen a loss of -21.23% in its stock price over the last five trading days. prnewswire.com reported 2025-05-01 that SAN FRANCISCO, May 1, 2025 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 8, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m.
NKTR’s Market Performance
Nektar Therapeutics (NKTR) has seen a -21.23% fall in stock performance for the week, with a 24.82% gain in the past month and a -12.34% plunge in the past quarter. The volatility ratio for the week is 9.45%, and the volatility levels for the past 30 days are at 12.09% for NKTR. The simple moving average for the past 20 days is -8.72% for NKTR’s stock, with a -40.39% simple moving average for the past 200 days.
Analysts’ Opinion of NKTR
Many brokerage firms have already submitted their reports for NKTR stocks, with Jefferies repeating the rating for NKTR by listing it as a “Buy.” The predicted price for NKTR in the upcoming period, according to Jefferies is $2 based on the research report published on April 11, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see NKTR reach a price target of $6. The rating they have provided for NKTR stocks is “Outperform” according to the report published on March 14th, 2025.
B. Riley Securities gave a rating of “Buy” to NKTR, setting the target price at $4 in the report published on January 08th of the current year.
NKTR Trading at -15.95% from the 50-Day Moving Average
After a stumble in the market that brought NKTR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.13% of loss for the given period.
Volatility was left at 12.09%, however, over the last 30 days, the volatility rate increased by 9.45%, as shares surge +19.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.11% lower at present.
During the last 5 trading sessions, NKTR fell by -22.11%, which changed the moving average for the period of 200-days by -58.38% in comparison to the 20-day moving average, which settled at $0.6729. In addition, Nektar Therapeutics saw -33.92% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NKTR starting from Zalevsky Jonathan, who sale 10,300 shares at the price of $1.01 back on Feb 19 ’25. After this action, Zalevsky Jonathan now owns 316,604 shares of Nektar Therapeutics, valued at $10,403 using the latest closing price.
Wilson Mark Andrew, the Chief Legal Officer of Nektar Therapeutics, sale 11,040 shares at $1.01 during a trade that took place back on Feb 19 ’25, which means that Wilson Mark Andrew is holding 324,292 shares at $11,150 based on the most recent closing price.
Stock Fundamentals for NKTR
Current profitability levels for the company are sitting at:
- -0.92 for the present operating margin
- 0.69 for the gross margin
The net margin for Nektar Therapeutics stands at -1.21. The total capital return value is set at -0.38. Equity return is now at value -124.10, with -33.90 for asset returns.
Based on Nektar Therapeutics (NKTR), the company’s capital structure generated 0.63 points at debt to capital in total, while cash flow to debt ratio is standing at -1.71. The debt to equity ratio resting at 1.69. The interest coverage ratio of the stock is -3.23.
Currently, EBITDA for the company is -86.7 million with net debt to EBITDA at -0.64. When we switch over and look at the enterprise to sales, we see a ratio of 1.76. The receivables turnover for the company is 61.17for trailing twelve months and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.26.
Conclusion
To sum up, Nektar Therapeutics (NKTR) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
